Ocular Therapeutix

Biotech & Life Sciences · Bedford, United States · Founded 2006 · IPO 2014

Biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye

Valuation $1.20B

Revenue $52M

Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Talent graph

Ocular Therapeutix's talent

Book a demo to see the people

Founders /100 quality score

Key operators quality score

Potential founders likely future founders

Startup mafia 4 alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

15 investors on Ocular Therapeutix's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 15 investors entered at this stage

Great Point Partners

Acuta Capital Partners

Versant Ventures

Ascension Ventures

SV Health Investors

Opaleye Management

Deep Track Capital

Baxter International

Ascension

TCGX

Logos Capital

Polaris Partners

Surveyor Capital

Venrock Healthcare Capital Partners

Perceptive Advisors

Ocular Therapeutix mafia

Startups founded by Ocular Therapeutix alumni

Former Ocular Therapeutix employees who went on to start their own companies. Sorted by Dealroom signal score.

OstialEst. 2009

Fred KhosraviUnited States

Signal score76

hC BioscienceEst. 2021

Leslie WilliamsUnited States

Signal score61

Pandion TherapeuticsEst. 2016

ACAlan CraneUnited States

Signal score58

SincerelyEst. 2011

Brian KennedyUnited States

Signal score54

Book a demo to explore the full alumni network →

Global footprint

Where Ocular Therapeutix has talent and traffic

Workforce by country

🇺🇸 United States · Bedford HQ

Book a demo for the full country breakdown

Web traffic by country

11K monthly visits
across markets

🇺🇸 United States70.9%

🇮🇳 India15.5%

🇧🇪 Belgium8.2%

🇨🇦 Canada6.4%

🇩🇪 Germany1.8%

Top 5 markets shown

Patent intelligence

$31M patent portfolio · 34 active families

Estimated portfolio value

$31M

2.6% of market cap · 17.6× smaller than top peer ChemoCentryx ($550M)

34 active patent families

Where Ocular Therapeutix innovates BiodegradationBiologyBiomedical engineeringImplantOcular disease

Where Ocular Therapeutix concentrates vs peers

Each axis is a top-10 topic across Ocular Therapeutix and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Ocular Therapeutix

An AI-synthesized read of the highest-engagement posts about Ocular Therapeutix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ocular Therapeutix on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles